S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.26%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
NASDAQ:ACRX

AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News

$0.31
-0.01 (-3.17%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.29
▼
$0.32
50-Day Range
$0.18
▼
$0.35
52-Week Range
$0.16
▼
$1.19
Volume
1.98 million shs
Average Volume
1.85 million shs
Market Capitalization
$45.01 million
P/E Ratio
1.05
Dividend Yield
N/A
Price Target
$5.00

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
100.0% Downside
$0.00 Price Target
Short Interest
Bearish
8.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.41
Upright™ Environmental Score
News Sentiment
0.81mentions of AcelRx Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$10,208 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From $0.05 to ($0.12) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

991st out of 1,122 stocks

Pharmaceutical Preparations Industry

493rd out of 551 stocks

See Top Rated MarketRank™ Stocks Here
ACRX stock logo

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals in a research note on Wednesday. They issued a "sell" rating on the stock.

AcelRx Pharmaceuticals Price Performance

Shares of AcelRx Pharmaceuticals stock traded down $0.03 during trading on Wednesday, reaching $0.29. 48,221 shares of the company traded hands, compared to its average volume of 3,854,710. AcelRx Pharmaceuticals has a 1-year low of $0.16 and a 1-year high of $1.19. The company has a 50 day moving average price of $0.24 and a 200-day moving average price of $0.28. The firm has a market capitalization of $43.05 million, a PE ratio of 1.10 and a beta of 0.44.

AcelRx Pharmaceuticals (NASDAQ:ACRX - Get Rating) last released its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.06). During the same quarter last year, the company posted ($0.08) EPS. Equities research analysts expect that AcelRx Pharmaceuticals will post 0.05 earnings per share for the current year.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

August 12, 2022 | seekingalpha.com
AcelRx Pharma stock falls ~17% premarket after Q2 results, large runup in shares
August 12, 2022 | seekingalpha.com
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2022 Results - Earnings Call Transcript
August 17, 2022 | Investing Daily (Ad)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
August 11, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates
August 11, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022
August 11, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
August 10, 2022 | americanbankingnews.com
AcelRx Pharmaceuticals (NASDAQ:ACRX) Research Coverage Started at StockNews.com
August 17, 2022 | Investing Daily (Ad)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
August 9, 2022 | americanbankingnews.com
AcelRx Pharmaceuticals (ACRX) to Release Earnings on Thursday
August 2, 2022 | americanbankingnews.com
AcelRx Pharmaceuticals (NASDAQ:ACRX) Earns Sell Rating from Analysts at StockNews.com
August 1, 2022 | americanbankingnews.com
Short Interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Increases By 81.4%
July 28, 2022 | finance.yahoo.com
AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022
July 25, 2022 | americanbankingnews.com
AcelRx Pharmaceuticals (NASDAQ:ACRX) Receives New Coverage from Analysts at StockNews.com
July 8, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals (NASDAQ:ACRX) shareholders are up 44% this past week, but still in the red over the last three years
May 19, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
May 19, 2022 | finance.yahoo.com
Why AcelRx Pharma Shares Are Trading Higher Today?
May 18, 2022 | seekingalpha.com
AcelRx Pharmaceuticals, Inc.'s (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call Transcript
May 16, 2022 | seekingalpha.com
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call Transcript
May 16, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 13, 2022 | finance.yahoo.com
Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates
May 10, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia
April 27, 2022 | finance.yahoo.com
AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program
April 21, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022
March 31, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures
March 29, 2022 | finance.yahoo.com
AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit
March 14, 2022 | seekingalpha.com
AcelRx stock falls 15% after HC Wainwright downgrade on 'disappointing quarter'
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Company Calendar

Last Earnings
8/11/2022
Today
8/17/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRX
CUSIP
N/A
CIK
1427925
Web
www.acelrx.com
Phone
(650) 216-3500
Fax
650-216-6500
Employees
43
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.00
High Stock Price Forecast
$0.00
Low Stock Price Forecast
$10,000,000.00
Forecasted Upside/Downside
+1,536.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.29
Trailing P/E Ratio
1.05
Forward P/E Ratio
6.11
P/E Growth
N/A
Net Income
$-35,100,000.00
Net Margins
1,588.91%
Pretax Margin
1,589.01%
Return on Equity
N/A
Return on Assets
-48.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.81
Quick Ratio
1.76

Sales & Book Value

Annual Sales
$2.82 million
Price / Sales
15.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
1.39

Miscellaneous

Outstanding Shares
147,332,000
Free Float
139,229,000
Market Cap
$45.01 million
Optionable
Optionable
Beta
0.44

Key Executives

  • Mr. Vincent J. Angotti (Age 54)
    CEO & Director
    Comp: $915.29k
  • Dr. Pamela Pierce Palmer M.D. (Age 59)
    Ph.D., Co-Founder, Chief Medical Officer & Director
    Comp: $682k
  • Mr. Raffi Mark Asadorian (Age 53)
    Chief Financial Officer
    Comp: $623.1k
  • Mr. Lawrence G. Hamel (Age 70)
    Consultant
  • Mr. Anil N. Dasu (Age 59)
    Chief Engineering Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ACRX Stock - Frequently Asked Questions

Should I buy or sell AcelRx Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRX shares.
View ACRX analyst ratings or view top-rated stocks.

What is AcelRx Pharmaceuticals' stock price forecast for 2022?

2 Wall Street analysts have issued twelve-month target prices for AcelRx Pharmaceuticals' shares. Their ACRX share price forecasts range from $10,000,000.00 to $0.00. On average, they anticipate the company's share price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for ACRX or view top-rated stocks among Wall Street analysts.

How have ACRX shares performed in 2022?

AcelRx Pharmaceuticals' stock was trading at $0.56 at the beginning of the year. Since then, ACRX stock has decreased by 44.6% and is now trading at $0.31.
View the best growth stocks for 2022 here.

When is AcelRx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ACRX earnings forecast.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) announced its quarterly earnings results on Thursday, August, 11th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, meeting analysts' consensus estimates of ($0.06). During the same period in the prior year, the firm posted ($0.08) earnings per share.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Values First Advisors Inc. (0.52%), Virtu Financial LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adrian Adams, Mark G Edwards and Vincent J Angotti.
View institutional ownership trends.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $0.31.

How much money does AcelRx Pharmaceuticals make?

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $45.67 million and generates $2.82 million in revenue each year. The specialty pharmaceutical company earns $-35,100,000.00 in net income (profit) each year or $0.29 on an earnings per share basis.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.